Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.

BMJ (Clinical research ed.) - 25 May 1991

Ranieri E, Ryall R G, Morris C P, Nelson P V, Carey W F, Pollard A C, Robertson E F

Abstract excerpt

OBJECTIVE: To assess the effectiveness of a two tier neonatal screening strategy for cystic fibrosis, which combines estimation of immunoreactive trypsinogen followed by direct gene analysis in dried blood spot samples collected at age 5 days. DESIGN: Prospective study of two tier screening strategy. The first tier of testing immunoreactive trypsinogen concentration was measured in dried blood spot samples from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Infant, Newborn

Share to Mutation

Share to Neonatal Screening

Source

Open in PubMed Open full text

Identifiers

PMID: 2043846
DOI: 10.1136/bmj.302.6787.1237
PMCID: PMC1669924

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.PMID 2043846Read ↗

Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.Semantic proximity Read ↗

Neonatal screening for cystic fibrosis in the Trent region (UK): two-stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step.Semantic proximity Read ↗

Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.Semantic proximity Read ↗

Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history.Semantic proximity Read ↗

Cystic fibrosis screening in neonates--measurement of immunoreactive trypsin and direct genotype analysis for delta F508 mutation.Semantic proximity Read ↗

Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.Semantic proximity Read ↗

Newborn screening for cystic fibrosis: techniques and strategies.Semantic proximity Read ↗

Thirty-years of screening for cystic fibrosis in East Anglia.Semantic proximity Read ↗

Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.Semantic proximity Read ↗

Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.Semantic proximity Read ↗

Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis.Semantic proximity Read ↗

Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.